COVID-19: Weekly Summary (December 08-14, 2025)

This week the little corner of the internet I read felt like a patchwork of worry, blame, and a sort of tired curiosity about what comes next with COVID-19. Some posts read like alarm bells from the lab bench. Some sounded like arguments in a kitchen about who did what wrong. Some were practical, nudging at the same problem from the regulatory angle. I would describe them as a mixed bag — anxious, skeptical, occasionally sharp — and oddly intimate, like overhearing neighbours at the bus stop swap versions of the same story.

What kept coming up

There were a few repeating threads. One was biological: claims about population-level immune damage after waves of Omicron, with numbers and charts and comparisons that make your stomach drop if you are the cautious sort. Another was institutional: calls to check regulators and health officials, because numbers get loose when politics pushes against science. And then a political thread: arguments about who wanted restrictions, who resisted them, and whether society was brave or oddly obedient. If you follow one blog or another this week, you probably saw pieces tugging at these same ropes from different ends.

The immune system worries: small numbers, big feelings

Two posts in particular put the immune system front and centre. Naked Capitalism flagged a worrying pattern about mass SARS-CoV-2 infections and how they might chip away at lymphocyte counts. They talked about persistent reductions across lymphocyte subsets. To me, it feels like someone pointing at a slow leak in a tyre: not dramatic while you stand there, but walking away with a flat tire later is still a real problem.

Then Rintrah dove into a study from China about the BA.5.2/BF.7 Omicron wave. The headline figure was the kind that sticks: T cell counts 10 percent below normal, persisting for nearly 20 months. They also mentioned drops in B cells, with older people and folks with cardiovascular disease hit hardest. The post floated a stark, unsettling analogy: a latent, slow-burn phase of immune damage not unlike how AIDS first showed us subtle immune weaknesses that later mattered in big ways. That is not to say the two are the same, but the comparison is meant to jolt you into thinking long term.

Both pieces worried about the downstream stuff: more routine respiratory infections, a creeping increase in vulnerability, and then the societal ripple effects when a chunk of the population is quietly less resilient. They also hinted at a tricky idea: small average drops in cell counts can add up across a whole country. Like pruning a hedge a little each year until it looks noticeably worse, not because one cut was catastrophic, but because cuts kept happening.

If you want the charts and the little qualifications, those are there. The writing nudges you to pay attention to the data viz, because the graphs do more talking than the gentle prose.

The message from regulators and mistakes that matter

There was a different tone in the piece about the FDA memo. Jeremy Faust, MD reported that the FDA vaccine chief, Dr. Vinay Prasad, said at least 10 pediatric deaths followed COVID vaccines. Inside the agency, the numbers were different: somewhere between zero and seven, according to internal memos. Numbers like these make people distrustful. I’d say that discrepancy reads as sloppy communication at best and as a misfire that could feed conspiracy-minded readers at worst.

The point wasn’t just the raw math. The point was about how an agency speaks in public. When a high-level person throws an incorrect number into the room, even if it is off by a handful, it cascades. It becomes a meme, a banner on social feeds, a talking point for folks who already distrust vaccines. The post suggested the risk from pediatric vaccinations is low, but that the messaging around those risks needed to be tighter.

This ties back to the broader theme: when trust is brittle, slight errors leak into big cracks. The piece made a quiet but sharp point: agencies have to be meticulous with numbers because the public will seize on the smallest inconsistency.

Technology, oversight, and the slow creep of AI into medicine

On a slightly different axis, Judy Lin 林昭儀 summarized a conversation with Dr. Stephen M. Hahn about AI and healthcare. It felt less apocalyptic and more like a civic planning meeting for medicine. Hahn argued that AI will speed up innovation but only if we pair it with good data and careful oversight. He stressed training for clinicians and the need for human oversight.

To me, Hahn’s take is the kind of cautious optimism you hear when an old hand says, ‘This could be useful, but don’t hand over the keys.’ It’s the difference between leaving a child with a responsible neighbour and leaving them with a stranger who can do great stuff but also makes weird choices. The post ties into COVID because a lot of pandemic-era innovations and missteps involved data, algorithms, and clinical decisions. If AI gets loose without checks, mistakes — or just sloppy interpretations — could amplify the very kind of miscommunication we saw in the FDA memo episode.

Origins, geopolitics, and an old lab that won’t stop being a talking point

Sam Cooper ran a piece that reads like a history lesson with an edge. It discussed Dennis Molinaro’s book about China’s influence in Canada and also brought up the Winnipeg lab in the COVID origins debate. This is the political and diplomatic angle of the pandemic — where blame and narrative live.

The piece argued that foreign influence and elite networks rewired parts of Canadian policy over decades. It also said that the Winnipeg lab keeps getting pulled into the origins question, which in turn colors how outsiders — like the U.S. — view Canadian institutions. This is one of those stories that shows the pandemic wasn’t just a health crisis. It was also a diplomatic and reputational one. Like a soccer team that loses a match but then gets accused of throwing it, everyone starts to question motives, and the original match becomes a kind of Rorschach test.

Voices arguing about public appetite for restrictions and what the pandemic did to society

This week's commentary also had the moralizing sort. Richard Hanania pushed back against the populist narrative that elites imposed restrictions on a reluctant public. He argued the public generally wanted stricter measures for safety, which flips a common story on its head. That ties into the other end of the spectrum where Quoth the Raven wrote an angrier piece. They argued that society responded with fear, that the young were bent into service of protecting the elderly, and that the pandemic revealed a kind of cowardice.

So you have two different takes that almost look like they’re shouting past each other. One says people mostly wanted protection; the other says the reaction was morally backward, a sign of malaise. Both pieces care about national character and both make sharp claims about what people wanted and how culture shifted. Neither has the last word.

If I had to put it bluntly: some writers saw a cautious public asking for rules, like folks asking for a handrail on a slippery stair. Others saw a society that lost its nerve, like a community that refuses to step outside during a little rain. Both images are vivid, and both tap into current grievances.

Crosscutting patterns I kept noticing

• Distrust of institutions. That thread runs from the FDA memo to the politics piece about foreign influence. The tone is often either frustrated or suspicious. People are asking who is checking the checkers.

• Long-term health fear. The immune-dysfunction posts are the clearest example. They are not shouting headlines so much as nudging you toward worrying in the background, like a dripping tap.

• Politics slants science. It’s obvious but worth saying: the pandemic is still being parsed in political terms. Whether the argument is about elites, populism, or foreign influence, the science gets pulled into broader battles.

• Demand for better data. Several writers kept pointing at data visualization or memos or studies and saying, ‘Look at this.’ There’s an insistence that better charts and cleaner calculations could calm conversations a little.

Points of agreement and disagreement

Agreement shows up in surprising places. Most writers want clarity. They want fewer sloppy public statements and better numbers. They want better explanations about what immune changes mean in real life, not just scary-sounding phrases pulled out of lab reports.

Where they disagree is on the story that sits around the numbers. Is the public brave or cowed? Were restrictions mainly elite imposition or public demand? Does a 10 percent drop in a cell count mean a future wave of trouble or a minor wobble that won’t matter in practical terms? Those are not just scientific questions. They are moral and political questions, too.

Little things that annoyed me, in a human way

A few posts recycled the same broad claims about COVID policy without much new evidence. You can feel the echo: the fundraising posts kept bringing up past critiques of pandemic-era government policy, almost like a favorite old tune at a family gathering. It’s fine to remind people, but repetition without new facts can feel like turning the same key in a few different doors.

Also, the language in some posts leaned toward alarm without careful qualifying. People love a strong sentence, but it’s the careful stats that keep you honest. That said, the alarm sometimes felt justified. When a study says whole-population T cells are still down 20 months later, alarm seems sensible.

What this batch nudges me toward thinking about next

• Watch for follow-up studies on immune markers. Single studies can be noisy. If other groups confirm the T cell and B cell findings, that becomes a different class of problem.

• Keep an eye on institutional transparency. The FDA memo story is a small example of how numbers and narratives can diverge. The solution is not just arguing in public but fixing the pipeline where numbers move from analysis into statements.

• Pay attention to AI governance in medicine. Hahn’s take is worth bookmarking. There will be more AI tools making clinical predictions, and how regulators manage that will matter for trust.

• Expect the political arguments to keep getting louder. The pandemic roped in geopolitics, national identity, and culture. Those threads are not going away.

If you are curious to dig deeper, go to the original pieces. They have the charts, the quotes, and the footnotes that matter if you want to unpack claims one by one. The posts do a good job of nudging you where the data live, or where the memos sit, so you can make up your own mind.

A small, wandering thought — because human brains do this

This week of reading felt a bit like walking through an old market. One stall sells alarming jars of data, another offers sharp political tracts, and a third is handing out what looks like sensible civic advice about regulation. You stop at each stall, pick up an item, and you feel a little different when you leave each time. Maybe more worried. Maybe angrier. Maybe more determined to look at the charts.

That variety is not useless. It keeps the conversation alive. It makes the pandemic not an event that simply happened and ended, but a long conversation that keeps changing tone. The immune papers say, ‘Pay attention to biology.’ The policy pieces say, ‘Fix the institutions.’ The political essays say, ‘Don’t forget what we did to each other.’ All of them matter, but in different ways.

If one image helps: imagine pandemic reporting like a kitchen radio. Some stations play the same old song. Some switch to static. Some run an urgent newsflash. The cacophony can be tiring, but it also means someone, somewhere, is still trying to translate the noise into a clear set of next steps.

If you want the details: the pieces by Naked Capitalism and Rintrah are where the immune numbers live. The memo story is with Jeremy Faust, MD. The AI and regulatory perspective is in Judy Lin 林昭儀. The geopolitical and origins notes are in Sam Cooper. And if you want the cultural takes, read Richard Hanania and Quoth the Raven to get two very different moods.

There is more to say, sure. But the gist this week is simple and a bit nagging: watch the data, keep the regulators honest, and expect the politics to keep reshaping how people talk about health. The tea’s still hot on some of these takes, and the kettle’s whistling for more study and debate.